The study maps the neutralizing antigenic sites of type A12 foot-and-mouth disease virus to specific viral proteins (VP1 and VP3).
No takes yet. Share an insight, caveat, or question.
May guide FMDV vaccine antigen design; leaves open validation in animal models.
Baxt et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: